Wock­hardt sets up man­u­fac­tur­ing fa­cil­ity in Dubai

BioSpectrum (India) - - COMPANY NEWS -

Wock­hardt has set up its first fa­cil­ity in Mid­dle East for man­u­fac­tur­ing of NCEs (New Chem­i­cal En­ti­ties) cater­ing to the global mar­kets through its Dubai arm of its sub­sidiary Wock­hardt Bio AG.

With an aim to grow and fur­ther es­tab­lish their in­ter­na­tional pres­ence in phar­ma­ceu­ti­cal man­u­fac­tur­ing, Wock­hardt re­cently in­au­gu­rated a ‘state-of-the-art’ man­u­fac­tur­ing fa­cil­ity for the pro­duc­tion and pack­ag­ing of ster­ile dry pow­der in­jec­tion in Dubai. On ap­proval of the new drug by US FDA, this man­u­fac­tur­ing fa­cil­ity will be com­mis­sioned for com­mer­cial pro­duc­tion. Wock­hardt Bio AG man­u­fac­tur­ing fa­cil­ity is de­signed to meet stan­dards of var­i­ous in­ter­na­tional reg­u­la­tory agen­cies and the stan­dards as set by the Lo­cal Min­istry of Health. The fa­cil­ity meets the needs of Asep­tic Dry Pow­der In­jectable man­u­fac­tur­ing and fill­ing with a high qual­ity op­er­a­tion. This fa­cil­ity is ded­i­cated to launch its novel New Chem­i­cal En­ti­ties in the An­tibi­otics seg­ment to the world from UAE.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.